Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) EBITDA Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBITDA Margin for 11 consecutive years, with 6383.79% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 503096.0% to 6383.79% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 250494.23% through Dec 2025, up 25069616.0% year-over-year, with the annual reading at 32564.25% for FY2025, 3236523.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 6383.79% at Cartesian Therapeutics, up from 5334.9% in the prior quarter.
  • The five-year high for EBITDA Margin was 6383.79% in Q4 2025, with the low at 2149.07% in Q4 2023.
  • Average EBITDA Margin over 5 years is 418.63%, with a median of 8.08% recorded in 2022.
  • The sharpest move saw EBITDA Margin crashed -218399bps in 2023, then skyrocketed 529327bps in 2025.
  • Over 5 years, EBITDA Margin stood at 40.86% in 2021, then decreased by -15bps to 34.92% in 2022, then tumbled by -6254bps to 2149.07% in 2023, then soared by 163bps to 1352.83% in 2024, then surged by 372bps to 6383.79% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 6383.79%, 5334.9%, and 1607.09% for Q4 2025, Q2 2025, and Q1 2025 respectively.